{"disease":{"id":"primary-iga-nephropathy","name":"primary iga nephropathy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT04557462","title":"A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":540,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05797610","title":"A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":428,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03643965","title":"Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":365,"lead_sponsor_name":"Calliditas Therapeutics AB","has_results":true},{"nct_id":"NCT07074951","title":"Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy","phase":"NA","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"St. Petersburg State Pavlov Medical University","has_results":false},{"nct_id":"NCT06589752","title":"Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06137768","title":"A Trial of HRS-5965 Tablets in Primary IgA Nephropathy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":123,"lead_sponsor_name":"Chengdu Suncadia Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT04541043","title":"Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"Calliditas Therapeutics AB","has_results":true},{"nct_id":"NCT05847920","title":"Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":53,"lead_sponsor_name":"Guangdong Hengrui Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT04291781","title":"A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"RemeGen Co., Ltd.","has_results":false},{"nct_id":"NCT07498335","title":"Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04014335","title":"A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06922305","title":"Relative Bioavailability Study of HR19042 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT07498673","title":"A Study of YKST02 in Participants With Primary IgA Nephropathy","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT04887532","title":"A Trial of HR19042 Capsule in Healthy Chinese Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}